WO2018136832A1 - Dietary supplement for gastrointestinal inflammation and method for making the same - Google Patents
Dietary supplement for gastrointestinal inflammation and method for making the same Download PDFInfo
- Publication number
- WO2018136832A1 WO2018136832A1 PCT/US2018/014582 US2018014582W WO2018136832A1 WO 2018136832 A1 WO2018136832 A1 WO 2018136832A1 US 2018014582 W US2018014582 W US 2018014582W WO 2018136832 A1 WO2018136832 A1 WO 2018136832A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dietary supplement
- active agent
- broth
- transforming
- animal
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 71
- 206010064147 Gastrointestinal inflammation Diseases 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 141
- 241001465754 Metazoa Species 0.000 claims abstract description 66
- 239000013543 active substance Substances 0.000 claims abstract description 65
- 230000001131 transforming effect Effects 0.000 claims abstract description 54
- 239000013589 supplement Substances 0.000 claims abstract description 48
- 239000002244 precipitate Substances 0.000 claims abstract description 17
- 230000002496 gastric effect Effects 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 37
- 241000287828 Gallus gallus Species 0.000 claims description 25
- 235000013305 food Nutrition 0.000 claims description 25
- 244000118681 Iresine herbstii Species 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 14
- 235000009508 confectionery Nutrition 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 9
- 239000000017 hydrogel Substances 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 239000007937 lozenge Substances 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000010414 supernatant solution Substances 0.000 claims description 2
- 235000010633 broth Nutrition 0.000 description 71
- 239000000203 mixture Substances 0.000 description 47
- 230000008569 process Effects 0.000 description 31
- 239000007788 liquid Substances 0.000 description 30
- 230000004888 barrier function Effects 0.000 description 25
- 210000001578 tight junction Anatomy 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 22
- 230000002757 inflammatory effect Effects 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 210000004955 epithelial membrane Anatomy 0.000 description 16
- 230000008901 benefit Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000003124 biologic agent Substances 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 102000000591 Tight Junction Proteins Human genes 0.000 description 7
- 108010002321 Tight Junction Proteins Proteins 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003292 diminished effect Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 235000021472 generally recognized as safe Nutrition 0.000 description 6
- 230000007358 intestinal barrier function Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004317 gizzard Anatomy 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002036 drum drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 229940051866 mouthwash Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 230000005549 barrier dysfunction Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- -1 but not limited to Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102100035965 Gastrokine-1 Human genes 0.000 description 1
- 101710205777 Gastrokine-1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/08—Alcohol
- A23V2250/082—Ethanol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Definitions
- Patent Application 62/448,151 filed on January 19, 2017, which is also incorporated by reference in its entirety.
- the present subject matter relates generally to a dietary supplement, preparation, and method of delivery wherein the supplement promotes an antiinflammatory effect or a barrier-promoting effect on a human (or another mammalian) gastrointestinal (Gl) tract.
- the present subject matter provides dietary supplements comprising an alcohol soluble fraction of meat broths and/or stocks, and their equivalents, wherein the supplement repairs, protects, and/or strengthens an epithelial cell layer in at least an in vitro assay for tight junction formation.
- the present subject matter provides processes for making the supplements, including heat extracting a source tissue followed by alcohol treatment, as well as processes for alcohol treatment of available broths and stocks.
- epithelia In human physiology, there are two main types of epithelia, and each uses a distinct type of barrier mechanism.
- One epithelium is the Dermal structure, such as skin, that forms a barrier comprising multiple layers of keratinised squamous cells. The other is referred to as Internal epithelia, which is what lines the gut. Tight junctions create a paracellular barrier in epithelial cells, protecting them from the external environment. Tight junctions hold cells together and mediate the barrier function.
- the important role of the gut epithelial membrane in promoting and maintaining homeostasis in a healthy host is well-established and documented in the scientific literature.
- This natural barrier aids in important physiological functions such as nutrient uptake from the lumen into the host as well as serving as a sentry to keep toxic substances or pathogens from entering into the host.
- gut mucosa is in a constant state of flux characterized by breakdown, repair and renewal.
- Many publications document the structure function aspect of these processes and illustrate the important features and mechanisms involved in gut epithelial wound healing.
- the intestinal epithelium undergoes a wound healing process. Intestinal wound healing is dependent on the balance of three cellular events; restitution, proliferation, and differentiation of epithelial cells adjacent to the wounded area.
- Various regulatory peptides including growth factors like gastrokine 1 (AM P-18) and cytokines, modulate intestinal epithelial wound healing. As healing occurs, new and enhanced formation of tight junctions between cells occur. With time, mucosal barrier function is restored.
- Mucosal nutrients and growth factors like gastrokines are intermediary or end products of prokaryotic and eukaryotic metabolism. Tissues rich in metabolic activity generally have higher concentrations of the active compounds. Growth factors, structural proteins, and enzymes are synthesized from precursor molecules that have their own biochemical properties. Some may have biological activity, whereas others may require an "activation" cleavage or addition. Little is known about ratios of precursor to active molecules that are required to achieve optimal health. Most nutritional treatment protocols, regimens, and intervention strategies employ supplementation of one or more agents to the diet and rely on the host to provide other complementary factors to restore normal homeostasis.
- Nutrients such as L-glutamine, phosphatidylcholine, N-acetyl-D- glucosamine, and gamma-linolenic acid provide the fuel and building blocks used in repair. Their importance is suggested from studies showing that patients having gastrointestinal disorders either lack or have depressed levels of these nutrients in their gut secretions. Investigations are beginning to reveal that suppressed repair mechanisms may lead to more serious diseases, such as the case of down regulated AM P-18 genes in patients with gastric cancer.
- GRAS natural, generally recognized as safe
- food sources can be used to prepare a mixture of agents that can fortify normal physiological wound healing processes and strengthen/reinforce tight junction barrier function.
- the present disclosure includes a composition comprising an edible food product derived from a combination of hydrolyzed animal tissue, wherein the initial source material is a commercially available chicken broth.
- An effective composition includes the alcohol soluble components of the initial food source adjusted to appropriate levels. No pharma grade chemicals or synthetics are required or needed. Further, the action of these natural agents can be studied and measured for efficacy and potency in experimental models typically used for the evaluation of pharma products.
- the primary examples of the subject matter taught herein relate to supplements for improving human Gl tract health and integrity. However, it is understood that the teachings herein may be used for improving the Gl tract health and integrity in mammalian animals, specifically, livestock and/or domestic pets.
- agent i.e., agent and agents
- agents i.e., agent and agents
- an active agent may consist of one or more agents. Accordingly, any use of the term agent or agents should be recognized as being inclusive of both singular and plural embodiments and the specific version of the word used in any given context has simply been chosen for simplified clarity in the description.
- the present disclosure provides dietary supplement compositions and methods of making the same.
- the supplement compositions include alcohol soluble fractions of animal broths, or their equivalents, that strengthen, protect, and repair epithelial cell layers in (at least) an in vitro assay for tight function formation.
- the present subject matter provides processes for making the supplements, including heat extracting a source tissue followed by alcohol treatment, as well as processes for alcohol treatment of commercially available broths and stocks.
- the supplement compositions are based on the premise that unimpeded wound healing occurs when there are both growth factors and wound healing proteins available at concentrations, and in a format, that favor immediate recruitment.
- such compositions can be achieved by careful selection of proper starting materials, a gentle disruptive hydrolysis, and selective transformation of the heat digest with ethanol.
- the methods can include activating the broth solution with alcohol treatment, followed by sequestration of the active agent solution by phase separation techniques (e.g., removing any resulting precipitates from the active agent solution).
- the disclosed supplement composition can be derived from a GRAS natural food source, such as a digest of animal tissue containing a complex mixture of proteins, peptides, growth factors, and nutrients associated with healthy tight junctions and homeostasis.
- a GRAS natural food source such as a digest of animal tissue containing a complex mixture of proteins, peptides, growth factors, and nutrients associated with healthy tight junctions and homeostasis.
- the natural sources may include animal muscle tissue, such as stomachs, livers, and gizzards from chicken, bovine, krill, and sea urchins, among others.
- G AS natural food source is chicken gizzards.
- Another example of such a GRAS natural food source is commercially available chicken broth.
- the starting source material e.g., animal muscle tissue
- the starting source material is minced into small pieces, converted into a puree (or smooth paste), or subject to any other particle reduction mechanism that increases the surface area of the source material, and agents are released by a gentle heat or equivalent digestion.
- Soluble extracted agents are harvested by filtration followed by treatment with a transforming vehicle, such as, but not limited to, ethanol, to initiate flocculation and precipitation of insoluble components.
- the amount of transforming vehicle used can be varied to achieve optimal levels of enrichment to form the active agents. Transformation can be monitored visually or through the use or
- Alcohol soluble agents are decanted and combined.
- the transforming vehicle is removed by applying gentle heat and through evaporation.
- the active agents can be selectively harvested and processed into a liquid or dried supplement for delivery to consumers.
- the present disclosure provides a composition for improving gastrointestinal function comprising a mixture of edible food products derived from hydrolyzed animal smooth and/or skeletal muscle tissue, bones, or ligaments.
- the composition includes alcohol soluble components adjusted to functional concentrations.
- the composition can include agents with gastrokine activity.
- the disclosure further includes methods for preparation of a dietary supplement for improving gastrointestinal disorders, wherein the method comprises selecting a biological source, applying heat to the biological source to release a biological agent from the biological source, extracting the biological agent from the source to form an extracted agent, transforming the extracted agent with a food grade alcohol, removing the alcohol, and forming the dietary supplement using the remaining alcohol soluble components, wherein the dietary supplement includes the transformed active agent.
- the dietary supplement includes: a concentrated animal broth derived from an animal source, wherein the concentrated broth is activated by a transforming, wherein the transforming vehicle is an alcohol.
- the transforming vehicle is removed from the dietary supplement.
- the dietary supplement may be in the form of at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel.
- the dietary supplement includes at least 10 mg/mL of alcohol soluble components of an animal broth. More specifically, the dietary supplement may include at least 10 mg of protein derived from the alcohol soluble components of an animal broth per mL of culture media. The protein measurement may be used as a surrogate measurement for the concentration of the active agent in the dietary supplement.
- the dietary supplement may be provided in powdered form wherein there is at least 10 mg of protein per mL of powder. In liquid preparations, the dietary supplement may be adjusted, for example, to be at least 10% volume of concentrated protein solution to overall preparation volume. It is understood that these are merely illustrative examples of the dietary supplement composition and that other variations will be apparent to those skilled in the art based on the teachings provided herein.
- the dietary supplement may be in the form of at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel.
- the dietary supplement may be derived from commercially available chicken broth.
- the dietary supplement may be derived from an animal broth including one or more chicken gizzards.
- the dietary supplement is prepared by: transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating the active agent by removing precipitates; removing the transforming vehicle from the active agent; and forming the dietary supplement, wherein the dietary supplement includes the active agent.
- a method for preparing a dietary supplement for improving gastrointestinal functionality includes: selecting a biological source; applying heat to the biological source to release a biological agent from the biological source; isolating the biological agent from the biological source to form an isolated agent; transforming the isolated agent into an active agent by treating the extracted agent with an alcohol solution; and forming the dietary supplement using the alcohol soluble components, wherein the dietary supplement includes an effective dose of the active agent.
- the step of transforming the extracted agent into an active agent includes combining the extracted agent with an ethanol solution, decanting the supernatant, and concentrating the supernatant solution to form the active agent.
- Isolating the biological agent from the biological source to form an extracted agent may include filtering the biological source from the biological agent.
- the method further comprises, after transforming the extracted agent into the active agent, heating the active agent to reduce the alcohol content.
- the biological source is an animal protein.
- the biological source may be one or more chicken gizzards.
- the biological agent may be commercially available chicken stock.
- the method may further include the step of incorporating the dietary supplement into at least one of a food product, hydrogel, tablet, lozenge, vitamin, powder, liquid, candy, and gel.
- the step of transforming the extracted agent into an active agent by treating the extracted agent with an alcohol solution includes adding an amount of alcohol to the active agent in a 1:1 ratio by volume.
- a method for preparing a dietary supplement for improving gastrointestinal functionality includes: providing an animal broth; transforming the animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating an active agent by removing precipitates; removing the
- An object of the subject matter of the present disclosure is to provide a dietary supplement that promotes an anti-inflammatory effect or barrier- promoting effect on the human gastrointestinal tract.
- Another object of the subject matter of the present disclosure is to provide a dietary supplement that restores and/or improves an epithelial cell membrane integrity.
- Another object of the subject matter of the present disclosure is to provide methods of preparation of such supplements.
- Another object of the subject matter of the present disclosure is to provide methods of delivery of such supplements.
- Another object of the subject matter of the present disclosure is to provide dietary supplements including an alcohol soluble fraction of meat broths and/or stocks, and their equivalents, wherein the supplement strengthens, protects, and repairs an epithelial cell layer in at least an in vitro assay for tight junction formation.
- Another object of the subject matter of the present disclosure is to provide processes for heat extracting a source tissue followed by alcohol treatment and to provide processes for alcohol treatment of available broths and stocks.
- An advantage of the subject matter of the present disclosure is that it provides supplements that promotes an anti-inflammatory effect or barrier- promoting effect on the human gastrointestinal tract.
- a further advantage of the subject matter of the present disclosure is that it provides a method of preparation that provides a supplement that does not require dilution and is compatible with a variety of common food and beverage ingredients to yield a desired flavor and texture profile.
- Another advantage of the subject matter of the present disclosure is the fortification of normal wound healing processes using natural agents (i.e., not chemically synthesized) useful in maintaining gastrointestinal health and addressing gastrointestinal disorders.
- Yet another advantage of the subject matter of the present disclosure is that it provides a cost-effective and efficient process for providing a supplement directly from biological sources.
- Still another advantage of the subject matter of the present disclosure is that is teaches that commercially available food products, such as animal broths, can be transformed into dietary supplements that improve epithelial cell membrane integrity and barrier functions.
- Fig. 1 is a schematic of a tight junction.
- Fig. 2 is a schematic overview of a TEE experimental design for measuring the integrity of Caco-2 epithelial membranes.
- FIG. 3 is flow chart illustrating an example of a process for preparing a dietary supplement according to the present disclosure.
- Fig. 4 is a flow chart of another example of a process for preparing a dietary supplement according to the present disclosure.
- Fig. 5 is a graph of TEER data versus time showing the effects of a broth derived supplement on tight junctions in TEER assays.
- Fig. 6 is a graph of TEER data versus time showing the effects of a gizzard derived supplement on tight junctions in TEER assays.
- Fig. 7 is a bar graph denoting the ability of two chicken broth preparations to induce increased cell proliferation.
- the supplements and methods described herein are based on the premise that unimpeded wound healing occurs when there is a full complement of both growth factors and wound healing proteins available at concentrations, and in a format, that favors immediate recruitment.
- Such composition can be achieved by: careful selection of proper starting material; a gentle disruptive hydrolysis, or other isolation or extraction technique to form extracted agents; selective transformation of the extracted agents with ethanol to form transformed agents; and sequestration of the active transformed agents by phase separation techniques, or their equivalents; and the formation of a dietary supplement using the alcohol soluble components of the transformed agents.
- the present supplement compositions can be derived from natural sources.
- the natural sources may comprise an unpurified digest of animal tissue containing a complex mixture of proteins, peptides, growth factors, and nutrients associated with healthy tight junctions and homeostasis.
- the natural sources may be carefully selected for their healing characteristics.
- An example of a natural source is smooth animal muscle tissue, such as, but not limited to, stomachs, livers, and gizzards, from such as chicken, bovine, krill, sea urchin, and others.
- the starting material is chicken gizzards, which are minced, and boiled in water for approximately 10-20 hours (e.g., 12 hours) to produce a chicken broth.
- the starting material can be commercially available meat broth (e.g., chicken broth, beef broth, among others).
- meat broth e.g., chicken broth, beef broth, among others.
- Other equivalent starting materials will be apparent to those skilled in the art based on the teachings provided herein.
- the animal broth can be treated with a transforming vehicle, such as, but not limited to, ethanol.
- a transforming vehicle such as, but not limited to, ethanol.
- the amount of transforming vehicle used can be varied to achieve optimal levels of enrichment to form the active composition.
- the transforming vehicle can be used to convert an otherwise non-reactive broth into a formulation that positively affects tight junctions in an in vitro assay. Transformation can be visually monitored and/or monitored by light microscopy, and/or monitored by measuring changes in optical density spectrophotometrically.
- the alcohol soluble solution (including the active agents) can be decanted, wherein the formed precipitants are removed from the active agent solution.
- the active agent rich fractions can be combined based on desirable qualities.
- the active agent solution can be selectively harvested by phase separation processes and processed into the supplement for delivery (e.g. concentrated solution, dried to a powder, converted to an elixir, among others).
- the method of forming the composition can include combining the animal source (e.g., chicken gizzards) and distilled or deionized water in a 1:1 ratio in any suitable processing equipment intended to sufficiently reduce particle size to yield a smooth paste free of visible intact pieces.
- the paste can then be heated between 75°C and 95°C in a closed system capable of continuous mixing for a time period between 9 and 18 hours.
- the mixture can then be removed from the heat source and the liquid can be separated from any solids (e.g., precipitates) by centrifugation, filtration, and/or decanting, among other separation methods.
- the collected liquid can be combined with food-grade ethanol in proportions ranging from 1:1 to 1:3 parts liquid to ethanol.
- the ethanol and collected liquid mixture can be maintained at a temperature between 2°C to 6°C for a time period between 8 and 120 hours, during which time a precipitate forms in the mixture.
- the precipitate can be removed by any conventional means including, but not limited to, centrifugation, filtration, vacuum filtration, decanting, among others.
- the collected liquid free of precipitate can then be further purified to remove the ethanol from the solution.
- the ethanol can be removed by employing any suitable process and/or processing equipment including, but not limited to, steam evaporation, rotary evaporation, heating the solution, among others. After the ethanol is removed, the solution can be further concentrated by suitable means in order to obtain a condensed active solution suitable for use.
- the dilute solution can be dried via any common drying process that reduces the moisture level to a point that the dried invention is shelf-stable (e.g., 0.1% to 3.0% moisture).
- Suitable drying processes include, but are not limited to, freeze-drying, spray drying, agglomeration, drum drying, among others.
- the supplement composition can include macronutrients, such as fats, carbohydrates, proteins, and fiber components.
- the extracted agents from the source can include glutamine, phytochemicals, carotenoids, vitamin E, vitamin C, zinc, selenium, or combinations thereof.
- the supplement composition can include various viscous fibers, such as, but not limited to guar gum, locust bean gum, xanthan gum, that may demonstrate an improved efficacy of the invention by forming a viscous 'bolus' that moves more slowly through the gut lumen than the untreated patient, thus increasing contact time with injured internal epithelial cells and allowing for increased efficacy in protecting, repairing, restoring, and maintaining healthy epithelial cells.
- various viscous fibers such as, but not limited to guar gum, locust bean gum, xanthan gum, that may demonstrate an improved efficacy of the invention by forming a viscous 'bolus' that moves more slowly through the gut lumen than the untreated patient, thus increasing contact time with injured internal epithelial cells and allowing for increased efficacy in protecting, repairing, restoring, and maintaining healthy epithelial cells.
- All materials, chemicals, and procedures used in the manufacture of the supplements taught herein may be "food safe” certified (e.g., designated as generally recognized as safe (GRAS) by the American Food and Drug Administration).
- the disclosed methods include selecting a source as a starting material (e.g. animal muscle tissue) that is minced into small pieces, converted into a puree (or smooth paste), or subject to any other particle reduction mechanism that increases the surface area of the starting material to then promote the release of the agent by a gentle heat or enzyme digestion.
- the soluble extracted agent can be collected by selective phase precipitation, filtration, or electrochemical or chromatographic methodologies.
- the delivery method of the supplement comprising the active agents depends on the specific application and biological efficacy desired.
- the active agents can be incorporated into a supplement that can be administered directly as a food, candy, drink, mouthwash, among others.
- the composition can be included in a dilute liquid form that may be utilized as a base for liquids such as hot or cold beverages (carbonated and/or still), soups, broths, syrups, juice, vegetable extracts, caffeinated beverages, among others.
- the composition can include flavor, color, among other additives.
- the supplement can be included in or as food additives, gummies, chewing gum, candy, lozenges, lollipops, antacid formulations, or hydrogels.
- the composition can be included in a formula using a liquid ingredient for the purpose of hydrating a powdered matrix, such as flours used in the manufacture of pastas, baked goods, snack foods, among many others.
- a powdered matrix such as flours used in the manufacture of pastas, baked goods, snack foods, among many others.
- the composition can be provided in a powder form that can be incorporated in recipes using dry ingredients that may be post-processed in any manner of methods specific to the end product.
- the dry form of the composition can be used in shelf-stable prepared meals, such as macaroni and cheese, among others.
- the supplement can include a timed-released coatings, hydrogels, or carriers that can modulate bioavailability.
- the formulation can also be combined with other identified agents that can promote Gl tract health, like probiotics.
- the composition can be formed into a supplement prepared using methods known to the skilled person.
- alcohol soluble components i.e., the composition solution free of participates
- gelling agents include agar, gellan gum, carrageenan, pectin, pre- gelatinized starch, modified starch and gelatin.
- thickening agents include furceliaran, locust bean gum, guar gum, gum Arabic and xanthan gum. These gelling agents and thickening agents can be used singly or in combination. The combination of a gelling agent and a thickening agent is especially preferable. Gelling agents and/or thickening agents exhibit an appropriate gelling ability and gel stabilizing ability and control the gel strength of the resulting gel.
- the supplement can be a nutritional supplement, which can be administered to the patient in a single dose, via multiple doses over a course of treatment, or on a routine ongoing basis.
- the supplement can be administered in a single dose once, twice, or three times per day.
- the supplement may be administered up to five times per day.
- the supplement may be administered between three to seven times per day.
- the supplement can be part of a vitamin regimen or probiotic supplement.
- the supplement can include a flavor to enhance its palatability, especially in a pediatric population.
- Artificial sweeteners may be added to complement: the flavor and mask the salty taste.
- Useful artificial sweeteners include saccharin, NutraSweet, sucraiose, acesu!fane-K (ace-K), etc,
- Preservatives may be added to help extend shelf life of the supplement. Persons knowledgeable in the art will be able to select the appropriate preservative, in the proper amount, to accomplish this result.
- Typical preservatives include, but are not limited to, potassium sorbate and sodium benzoate.
- the supplement can include suitable carbohydrates, lipids and proteins as are known to those skilled in the art of making nutritional formulas.
- suitable carbohydrates include, but are not limited to, hydroiyzed, intact, naturally and/or chemically modified starches sourced from corn, tapioca, rice or potato in waxy or non-waxy forms; and sugars such as glucose, fructose, lactose, sucrose, maltose, high fructose corn syrup, corn syrup solids, fructo-oligosaccharides, and mixtures thereof.
- Ma!todextrins are polysaccharides obtained from the acid or enzyme hydrolysis of starches (such as those from corn or rice).
- Fig. 1 is a schematic of an example of a tight junction.
- Differentiated human Caco-2 cells are a useful model of the intestinal barrier with functional tight junction complexes.
- Caco-2 cells can form an artificial epithelial cell membrane that can be challenged with nutrients and toxins. Integrity of this membrane can be monitored with a TEER assay format and agents can be screened for their ability to improve or destroy intestinal barrier function.
- a metric of enhanced protection of barrier function is the achievement of a level of TEER values 100% or higher than the control.
- Fig. 2 shows an overview of a TEER experimental design for measuring the integrity of Caco-2 epithelial membranes.
- trans-epithelial electrical resistance (TEER) readings are performed at discreet, designated time points (e.g., 0, 28, and 48 hours, etc.) using an epithelial voltohmmeter, such as the one sold under the trademark name EVOM2 by World Precision Instruments, or continuously (e.g., for 24 continuous hours, for 48 continuous hours, etc.) or at hourly intervals using a cell monitoring system, such as the one sold under the trademark name CellZscope by nanoAnalytics GmbH.
- a cell monitoring system such as the one sold under the trademark name CellZscope by nanoAnalytics GmbH.
- Higher potentials correspond to greater membrane integrity. The lower the potential, the more disruption of the membrane.
- the experimental design tests food grade samples for effects on intestinal barrier function in cultured intestinal cells.
- Caco-2 cells are cultured on plates (such as those sold under the trademark name Transwell by Corning Incorporated) and cultured for 21 days to form a model intestinal barrier. Subsequently, cells are treated with test compounds, with or without an
- inflammatory cocktail composed of proinflammatory cytokines and lipopolysaccharaide (LPS).
- the inflammatory cocktail treatment induces intestinal barrier dysfunction.
- Test compounds that prevent IC-induced barrier dysfunction may have anti-inflammatory cytokines and lipopolysaccharide (LPS).
- Test compounds that prevent IC-induced barrier dysfunction may have antiinflammatory and/or barrier-promoting activities.
- Test compounds that increase barrier function in healthy cells likely have barrier-promoting activities.
- genistein a soy isoflavone, is used as a positive control. Barrier function is determined by trans-epithelial electrical resistance (TEER) and reported and described in Equations 1 and 2.
- TEE ( ⁇ % Initial) 100 * (TEER 24 or 28 hours - TEE R o hour)/TEER o hour (1)
- TEER ( ⁇ % IC Normalized) 100 * TEER ( ⁇ % lnitial) sa mpie/ TEER ( ⁇ % lnitial)ic (2)
- the EVOM2 voltohmmeter On day 20 of growth, the EVOM2 voltohmmeter is prepared by plugging it in and placing the "chopstick" electrode in .1 M KOH. On day 21, the cultured Caco-2 cell samples are processed as follows, or equivalent.
- 24-well plates containing membrane inserts with Caco-2 cells are removed from a C02 incubator (37°C, 5% C02, ⁇ 91% Relative Humidity) and moved into a biosafety hood.
- the modified growth media is removed from both the basal and apical layers of the cell inserts.
- the cells are washed with sterile phosphate buffered solution and a Hanks Balanced Salt Solution (HBSS) is added to the apical (.2 ml) and basal layers (1 ml).
- HBSS Hanks Balanced Salt Solution
- the 24-well plates are returned to the C02 incubator and allowed to incubate for 30 minutes.
- a hotplate in the biosafety hood is set to 37°C and the EVOM2, along with the chopstick electrodes, are moved to the biosafety hood.
- the chopstick electrodes are submerged in 70% ethanol solution for 15 minutes and then held in the HBSS.
- each plate is removed from the incubator one by one and placed on the hot plate.
- the covers are removed and, using the "chopstick" electrodes, each insert is measured in triplicate. The average of the three measurements establishes a baseline for each insert.
- the HBSS is removed from both the apical and basal compartments and replaced with inflammatory cocktail (or experimental growth media, in the case of positive controls) and experimental media in the apical layer according to the experimental design.
- dry samples are prepared by weighing out 10 mg of material into 15 mL conical centrifuge tubes, re-suspending dry material in modified DM EM growth media, vortexing at 2000 PM for 30 seconds, and sonicating at 37°C for 20 minutes.
- the solutions are then filtered using a .2-micron syringe tip filter. This stock solution is then used to create samples of the desired concentration by diluting the sterile stock solutions further with the modified growth media.
- liquid samples are prepared by thawing liquid samples in a hot water bath at 37°C for about 5 minutes or until fully thawed, adding the volume of supplied liquid to modified DMEM growth media, and filtering the solutions using a .2-micron syringe tip filter. This stock solution is then used to create samples of the desired concentration by diluting the sterile stock solutions further with the modified growth media.
- the inflammatory cocktail is prepared by the following process: concentrated stock solutions of the necessary cytokines are stored in the -80°C freezer and properly aliquoted to minimize degradation from thaw-freeze cycles. The cytokine aliquots are removed from the freezer and brought into the hood for processing. The cytokines are added to the modified growth media to arrive at the final concentration of 50 ng/ml (TNF-a), 25 ng/ml (IL- ⁇ ), 50 ng/ml (IFN- ⁇ ), 1 ⁇ g/ml (Lipopolysaccharide).
- FIGs. 3 and 4 illustrate examples of processes for preparing dietary supplements according to the teachings presented herein. These examples are illustrative of the subject matter of this disclosure.
- Fig. 3 illustrates an example of a process for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method comprises the steps of: providing an animal broth; transforming the animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating an active agent by removing precipitates; removing the transforming vehicle from the active agent; and forming the dietary supplement, wherein the dietary supplement includes the active agent.
- the alcohol is ethanol.
- the process for preparing a dietary supplement for improving gastrointestinal functionality can include selecting an animal broth.
- the selected animal broth may be a commercially available chicken broth such as, for example, the animal broth sold under the trademark name Swanson Unsalted Chicken Broth by CSC Brand LP.
- the animal broth may be a different chicken broth or may be an animal broth other than a chicken broth, for example, a beef broth. Suitable animal broths will be recognized by those skilled in the art based on the practice of the inventions described herein.
- Suitable animal broths will be recognized by those skilled in the art based on the practice of the inventions described herein.
- the step of transforming the animal broth into an active agent by adding a transforming vehicle to the animal broth may include combining the animal broth with food-grade ethanol in proportions ranging from 1:1 to 1:3 parts liquid to ethanol.
- the ethanol and collected liquid mixture can be maintained at a temperature between 2°C to 6°C for a time period between 8 and 120 hours, during which time a precipitate forms in the mixture.
- the step of isolating an active agent by removing precipitates can be accomplished by any conventional means including, but not limited to, centrifugation, filtration, vacuum filtration, decanting, among others.
- the step of removing the transforming vehicle from the active agent can include further purification of the active agent by removing the ethanol from the solution.
- the ethanol can be removed by employing any suitable process and/or processing equipment including, but not limited to, steam evaporation, rotary evaporation, heating the solution, among others.
- the step of removing the transforming vehicle from the active agent can additionally include further concentration of the active agent in order to obtain a condensed active agent suitable for use.
- the dilute solution can be dried via any common drying process that reduces the moisture level to a point that the dried invention is shelf-stable (e.g., 0.1% to 3.0% moisture). Suitable drying processes include, but are not limited to, freeze-drying, spray drying, agglomeration, drum drying, among others. [0083] In an example of the process illustrated in Fig.
- the step of forming the dietary supplement, wherein the dietary supplement includes the active agent may include, as described in detail above, incorporating the active agent into a supplement that can be administered directly as an edible supplement in the form of a food, candy, drink, mouthwash, etc. Additional details as to the processes and compositions are included above in this detailed description.
- Fig. 4 illustrates an example of a process for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method comprises the steps of: selecting a biological source; applying heat to the biological source to release a biological agent from the biological source; isolating the biological agent from the biological source to form an extracted agent; transforming the extracted agent into an active agent by treating the extracted agent with an alcohol solution; and forming the dietary supplement, wherein the dietary supplement includes the active agent.
- the process for selecting a biological source may include selecting chicken gizzards as a biological source.
- another animal tissue may be used as the biological source.
- the process for applying heat to the biological source to release a biological agent from the biological source may include mincing the chicken gizzards (or other animal tissue), and then boiling them in water for approximately 10-20 hours (e.g., 12 hours) to produce a chicken broth.
- chicken gizzards can be combined with distilled or deionized water in a 1:1 ratio in any suitable processing equipment intended to sufficiently reduce particle size to yield a smooth paste (or puree) free of visible intact pieces.
- the paste can then be heated between 75°C and 95°C in a closed system capable of continuous mixing for a time period between 9 and 18 hours.
- isolating the biological agent from the biological source to form an extracted agent may include removing the heated biological source from the heat source and separating liquid from any solids (e.g., precipitates) by centrifugation, filtration, and/or decanting, among other separation methods.
- the separated liquid is the extracted agent.
- transforming the extracted agent into an active agent by treating the extracted agent with an alcohol solution includes combining the extracted agent (i.e., the separated liquid) with food-grade ethanol in proportions ranging from 1: 1 to 1:3 parts liquid to ethanol.
- the ethanol and liquid mixture can be maintained at a temperature between 2°C to 6°C for a time period between 8 and 120 hours, during which time a precipitate forms in the mixture.
- the precipitate can be removed by any conventional means including, but not limited to, centrifugation, filtration, vacuum filtration, decanting, among others.
- the collected liquid free of precipitate can then be further purified to remove the ethanol from the solution.
- the ethanol can be removed by employing any suitable process and/or processing equipment including, but not limited to, steam evaporation, rotary evaporation, heating the solution, among others.
- the solution can be further concentrated by suitable means in order to obtain a condensed active solution suitable for use.
- the dilute solution can be dried via any common drying process that reduces the moisture level to a point that the dried invention is shelf-stable (e.g., 0.1% to 3.0% moisture). Suitable drying processes include, but are not limited to, freeze-drying, spray drying, agglomeration, drum drying, among others.
- forming the dietary supplement, wherein the dietary supplement includes the active agent includes, as described in detail above, incorporating the active agent into a supplement that can be administered directly as an edible supplement in the form of a food, candy, drink, mouthwash, etc. Additional details as to the processes and compositions are included above in this detailed description.
- FIG. 5 is a graph of TEER data versus time showing the effects of a broth derived supplement on tight junctions in TEER assays.
- Fig. 6 is a graph of TEER data versus time showing the effects of a gizzard derived supplement on tight junctions in TEER assays.
- Figs. 5 and 6 are representative of results obtained by following the TEER experimental design for measuring the integrity of Caco-2 epithelial membranes described above with respect to Fig. 2.
- TEER readings above 100 are representative of restored or enhanced epithelial membrane integrity and enhanced barrier function in the epithelial membranes.
- the inflammatory cocktails resulted in diminished barrier function of the epithelial membrane throughout the 48-hour testing period.
- the untreated commercially available chicken broth, nor the 5 mg/mL liquid preparation of the alcohol-soluble components of the commercial chicken broth were able to fully counteract the effects of the inflammatory cocktail, each showing diminished barrier function of the epithelial membrane throughout the 48-hour testing period.
- the 10 mg/mL liquid preparation of the alcohol-soluble components of the commercial chicken broth showed increased barrier function throughout the majority of the 48-hour testing period. Accordingly, the results shown in Fig. 5 support the conclusion that a liquid-based dietary supplement including a concentration of approximately, or at least, 10 mg/mL of alcohol-soluble preparation derived from commercially available chicken broth may provide enhanced barrier function of tight junctions.
- the inflammatory cocktail resulted in diminished barrier function of the epithelial membrane throughout the 48-hour testing period.
- the 25 mg/mL powder preparation of an animal broth made from chicken gizzards was unable to counteract the inflammatory cocktail and, therefore, showed diminished barrier function of the epithelial membrane throughout substantially all of the 48-hour testing period.
- both the 25 mg/mL powder preparation of the alcohol-soluble components of an animal broth made from chicken gizzards and the 25 mg/mL liquid preparation of the alcohol-soluble components of an animal broth made from chicken gizzards showed increased barrier function throughout a statistically relevant portion of the 48-hour testing period. Accordingly, the results shown in Fig. 6 support the conclusion that both powder-based and liquid-based dietary supplements including a concentration of approximately, or at least, 25 mg/ML of the alcohol-soluble components of an animal broth made from chicken gizzards may provide enhanced barrier function of tight junctions.
- Figs. 5 and 6 are representative examples of testing that has been performed on the subject matter presented herein. Numerous assays were completed with redundant sources and preparations demonstrating repeatable results. [0097] Fig. 7 illustrates a pair of bar graphs showing the cell proliferation of a
- Caco-2 epithelial membrane when subjected to various compositions.
- mitogenesis was assayed by performing cell counts four days after exposing a confluent culture of indicator cells to the agent of interest, adding trypsin to prepare a suspension of single cells, and confirming cell separation while counting them in a hemocytometer. Mitogenic activity was assessed in each of the following preparations: chicken gizzard derived supplement using no alcohol extraction step (Sample 1), and chicken broth derived supplement that utilized an alcohol treatment step (Sample 2).
- compositions of ethanol-treated commercial chicken broth demonstrated superior cell proliferation relative to the control .
- compositions of ethanol-treated commercial chicken broth further demonstrated a dose dependency, with the higher concentrations showing greater cell proliferation.
- Greater cell proliferation represents a restoration and/or enhancement of the barrier function of the epithelial membrane and is suggestive of wound repair and healthy tight junctions.
- the subject matter provided herein supports a conclusion that, in the appropriate concentration, the alcohol-soluble components of both "off- the-shelf" commercially available animal broths, as well as animal broths developed from animal tissue such as chicken gizzards, demonstrate the ability to restore and/or improve epithelial membrane integrity and barrier function.
- TEE data demonstrated the effects of residual ethanol in the broth digests.
- TEER measurements were lower than the inflammatory cocktail tracings. Accordingly, this data demonstrates that there are advantages to completely removing any residual ethanol in the broth digests.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A dietary supplement for improving gastrointestinal functionality includes: an edible supplement comprising at least 10 mg/mL of alcohol soluble components of an animal broth. A method for preparing a dietary supplement for improving gastrointestinal functionality includes the steps of: transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating the active agent by removing precipitates; removing the transforming vehicle from the active agent; and forming the dietary supplement, wherein the dietary supplement includes the active agent.
Description
DIETARY SUPPLEMENT FOR GASTROINTESTINAL INFLAMMATION AND METHOD
FOR MAKING THE SAME
Cross-Reference to Related Applications
[0001] This application claims the benefit of priority to U.S. Provisional
Patent Application 62/448,151 filed on January 19, 2017, which is also incorporated by reference in its entirety.
Background of the Invention
[0002] The present subject matter relates generally to a dietary supplement, preparation, and method of delivery wherein the supplement promotes an antiinflammatory effect or a barrier-promoting effect on a human (or another mammalian) gastrointestinal (Gl) tract. Specifically, the present subject matter provides dietary supplements comprising an alcohol soluble fraction of meat broths and/or stocks, and their equivalents, wherein the supplement repairs, protects, and/or strengthens an epithelial cell layer in at least an in vitro assay for tight junction formation.
Further, the present subject matter provides processes for making the supplements, including heat extracting a source tissue followed by alcohol treatment, as well as processes for alcohol treatment of available broths and stocks.
[0003] In human physiology, there are two main types of epithelia, and each uses a distinct type of barrier mechanism. One epithelium is the Dermal structure, such as skin, that forms a barrier comprising multiple layers of keratinised squamous cells. The other is referred to as Internal epithelia, which is what lines the gut. Tight junctions create a paracellular barrier in epithelial cells, protecting them from the external environment. Tight junctions hold cells together and mediate the barrier function.
[0004] The important role of the gut epithelial membrane in promoting and maintaining homeostasis in a healthy host is well-established and documented in the scientific literature. This natural barrier aids in important physiological functions such as nutrient uptake from the lumen into the host as well as serving as a sentry to keep toxic substances or pathogens from entering into the host. There are ample examples showing that the gut mucosa is in a constant state of flux characterized by breakdown, repair and renewal. Many publications document the structure function aspect of these processes and illustrate the important features and mechanisms involved in gut epithelial wound healing.
[0005] Individuals with Gl tract disorders typically demonstrate impaired mucosal barrier function and disrupted tight junctions. Further, the scientific literature documents that many diseases are caused by or exacerbated by an underlying breakdown of this barrier or disruption of normal physiology. For example, oral mucositis, is an inflammatory and ulcerative injury of the mouth, throat, or Gl tract most commonly caused by chemo or radiation therapy for cancer. This condition has its onset upon the disruption of the mucosal surface of the mouth and other portions of the Gl tract. Both the epithelial layer and the underlying connective tissue of the oral cavity are affected. Cell death occurs and there is a loss of tight junction proteins, such as occludin and ZO-I, at the molecular level.
Consequently, there is a subsequent disruption of the tight junctions.
[0006] Upon injury, the intestinal epithelium undergoes a wound healing process. Intestinal wound healing is dependent on the balance of three cellular events; restitution, proliferation, and differentiation of epithelial cells adjacent to the wounded area. Various regulatory peptides, including growth factors like
gastrokine 1 (AM P-18) and cytokines, modulate intestinal epithelial wound healing. As healing occurs, new and enhanced formation of tight junctions between cells occur. With time, mucosal barrier function is restored.
[0007] Mucosal nutrients and growth factors like gastrokines are intermediary or end products of prokaryotic and eukaryotic metabolism. Tissues rich in metabolic activity generally have higher concentrations of the active compounds. Growth factors, structural proteins, and enzymes are synthesized from precursor molecules that have their own biochemical properties. Some may have biological activity, whereas others may require an "activation" cleavage or addition. Little is known about ratios of precursor to active molecules that are required to achieve optimal health. Most nutritional treatment protocols, regimens, and intervention strategies employ supplementation of one or more agents to the diet and rely on the host to provide other complementary factors to restore normal homeostasis.
[0008] Nutrients such as L-glutamine, phosphatidylcholine, N-acetyl-D- glucosamine, and gamma-linolenic acid provide the fuel and building blocks used in repair. Their importance is suggested from studies showing that patients having gastrointestinal disorders either lack or have depressed levels of these nutrients in their gut secretions. Investigations are beginning to reveal that suppressed repair mechanisms may lead to more serious diseases, such as the case of down regulated AM P-18 genes in patients with gastric cancer.
[0009] Restoration of normal healthy function can be facilitated by traditional medicinal therapies, nutritional supplements, diet, or probiotics. There is no consensus on the optimal levels of the above-mentioned nutrients and growth factors in the gut milieu that maintain a healthy Gl tract. However, improved
mucosal health has been reported in humans after daily ingestion of vitamins and other nutrients at dosage levels reported to be from 100 mg/day up to 1500 mg/day. These studies also demonstrate that, through oral administration, these compounds are directly absorbed from the gut lumen and incorporated into glycans and glycoproteins of the intestinal mucosa.
[0010] The efficacy of gastrokines to treat gastrointestinal inflammation in animal models was achieved at dosages ranging from lmg/kg to 100 mg/kg. The route of administration (specifically intraperitoneal or subcutaneous injections, as well as topically with no carrier) did not seem to affect efficacy. However, dose response curves imply a minimum dosage threshold to achieve desired outcomes.
[0011] The plethora of options at the local health stores suggests that non- medicinal products can afford benefits, Unfortunately, not all of these alternative therapies have been evaluated in well-control population studies.
[0012] Accordingly, there is a need for a dietary supplement that can be shown in well-controlled studies, to be efficacious in aiding in protection and strengthening of the gastrointestinal tract and repair of gastrointestinal
inflammation-associated injury. In addition, there is a need for dietary components and mixtures of nutrients that are effective in improving intestinal barrier function without the requirement of pharma grade agents. Lastly, there is a need for a cost- effective and efficient process for preparing a dietary supplement, particularly directly from a biological source.
Brief Summary of the Description
[0013] The underlying principal to the subject matter described herein is that natural, generally recognized as safe ("GRAS"), food sources can be used to prepare
a mixture of agents that can fortify normal physiological wound healing processes and strengthen/reinforce tight junction barrier function. In a primary example, the present disclosure includes a composition comprising an edible food product derived from a combination of hydrolyzed animal tissue, wherein the initial source material is a commercially available chicken broth. An effective composition includes the alcohol soluble components of the initial food source adjusted to appropriate levels. No pharma grade chemicals or synthetics are required or needed. Further, the action of these natural agents can be studied and measured for efficacy and potency in experimental models typically used for the evaluation of pharma products.
[0014] The primary examples of the subject matter taught herein relate to supplements for improving human Gl tract health and integrity. However, it is understood that the teachings herein may be used for improving the Gl tract health and integrity in mammalian animals, specifically, livestock and/or domestic pets.
[0015] The term singular and plural versions of the term "agent" (i.e., agent and agents) are used interchangeably throughout this disclosure. Particularly, it is recognized that, as used herein, an active agent may consist of one or more agents. Accordingly, any use of the term agent or agents should be recognized as being inclusive of both singular and plural embodiments and the specific version of the word used in any given context has simply been chosen for simplified clarity in the description.
[0016] In its development, the subject matter provided herein was tested for its effect on tight junctions. Tight junctions were chosen to study because of their importance in gut health and the availability of well-controlled in vitro models. The subject matter disclosed herein teaches that a composition of alcohol soluble agents
derived from G AS food substances can interact with tight junctions to enhance their function to protect against inflammatory induced injury and promote a prolonged barrier function greater than that observed in control conditions.
[0017] To this end, the present disclosure provides dietary supplement compositions and methods of making the same. In certain embodiments, the supplement compositions include alcohol soluble fractions of animal broths, or their equivalents, that strengthen, protect, and repair epithelial cell layers in (at least) an in vitro assay for tight function formation. Further, the present subject matter provides processes for making the supplements, including heat extracting a source tissue followed by alcohol treatment, as well as processes for alcohol treatment of commercially available broths and stocks.
[0018] The supplement compositions are based on the premise that unimpeded wound healing occurs when there are both growth factors and wound healing proteins available at concentrations, and in a format, that favor immediate recruitment. In examples provided herein, such compositions can be achieved by careful selection of proper starting materials, a gentle disruptive hydrolysis, and selective transformation of the heat digest with ethanol. The methods can include activating the broth solution with alcohol treatment, followed by sequestration of the active agent solution by phase separation techniques (e.g., removing any resulting precipitates from the active agent solution).
[0019] Specifically, the disclosed supplement composition can be derived from a GRAS natural food source, such as a digest of animal tissue containing a complex mixture of proteins, peptides, growth factors, and nutrients associated with healthy tight junctions and homeostasis. For example, the natural sources may
include animal muscle tissue, such as stomachs, livers, and gizzards from chicken, bovine, krill, and sea urchins, among others. One specific example of such a G AS natural food source is chicken gizzards. Another example of such a GRAS natural food source is commercially available chicken broth.
[0020] In a primary example, the starting source material (e.g., animal muscle tissue) is minced into small pieces, converted into a puree (or smooth paste), or subject to any other particle reduction mechanism that increases the surface area of the source material, and agents are released by a gentle heat or equivalent digestion. Soluble extracted agents are harvested by filtration followed by treatment with a transforming vehicle, such as, but not limited to, ethanol, to initiate flocculation and precipitation of insoluble components. The amount of transforming vehicle used can be varied to achieve optimal levels of enrichment to form the active agents. Transformation can be monitored visually or through the use or
instrumentation. Alcohol soluble agents are decanted and combined. The transforming vehicle is removed by applying gentle heat and through evaporation. The active agents can be selectively harvested and processed into a liquid or dried supplement for delivery to consumers.
[0021] The present disclosure provides a composition for improving gastrointestinal function comprising a mixture of edible food products derived from hydrolyzed animal smooth and/or skeletal muscle tissue, bones, or ligaments. In an example, the composition includes alcohol soluble components adjusted to functional concentrations. The composition can include agents with gastrokine activity.
[0022] The disclosure further includes methods for preparation of a dietary supplement for improving gastrointestinal disorders, wherein the method comprises selecting a biological source, applying heat to the biological source to release a biological agent from the biological source, extracting the biological agent from the source to form an extracted agent, transforming the extracted agent with a food grade alcohol, removing the alcohol, and forming the dietary supplement using the remaining alcohol soluble components, wherein the dietary supplement includes the transformed active agent.
[0023] In an example of a dietary supplement for improving gastrointestinal functionality according to the teachings provided herein, the dietary supplement includes: a concentrated animal broth derived from an animal source, wherein the concentrated broth is activated by a transforming, wherein the transforming vehicle is an alcohol. In some examples, the transforming vehicle is removed from the dietary supplement. The dietary supplement may be in the form of at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel.
[0024] In another example of a dietary supplement for improving gastrointestinal functionality according to the teachings provided herein, the dietary supplement includes at least 10 mg/mL of alcohol soluble components of an animal broth. More specifically, the dietary supplement may include at least 10 mg of protein derived from the alcohol soluble components of an animal broth per mL of culture media. The protein measurement may be used as a surrogate measurement for the concentration of the active agent in the dietary supplement. For example, the dietary supplement may be provided in powdered form wherein there is at least 10 mg of protein per mL of powder. In liquid preparations, the dietary supplement may
be adjusted, for example, to be at least 10% volume of concentrated protein solution to overall preparation volume. It is understood that these are merely illustrative examples of the dietary supplement composition and that other variations will be apparent to those skilled in the art based on the teachings provided herein.
[0025] The dietary supplement may be in the form of at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel. The dietary supplement may be derived from commercially available chicken broth. In another example, the dietary supplement may be derived from an animal broth including one or more chicken gizzards. In some embodiments, the dietary supplement is prepared by: transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating the active agent by removing precipitates; removing the transforming vehicle from the active agent; and forming the dietary supplement, wherein the dietary supplement includes the active agent.
[0026] In one example, a method for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method includes: selecting a biological source; applying heat to the biological source to release a biological agent from the biological source; isolating the biological agent from the biological source to form an isolated agent; transforming the isolated agent into an active agent by treating the extracted agent with an alcohol solution; and forming the dietary supplement using the alcohol soluble components, wherein the dietary supplement includes an effective dose of the active agent.
[0027] In certain embodiments of the method, the step of transforming the extracted agent into an active agent includes combining the extracted agent with an
ethanol solution, decanting the supernatant, and concentrating the supernatant solution to form the active agent. Isolating the biological agent from the biological source to form an extracted agent may include filtering the biological source from the biological agent. In some examples, the method further comprises, after transforming the extracted agent into the active agent, heating the active agent to reduce the alcohol content. In some embodiments, the biological source is an animal protein. For example, the biological source may be one or more chicken gizzards. In other examples, the biological agent may be commercially available chicken stock.
[0028] The method may further include the step of incorporating the dietary supplement into at least one of a food product, hydrogel, tablet, lozenge, vitamin, powder, liquid, candy, and gel. Within the method, the step of transforming the extracted agent into an active agent by treating the extracted agent with an alcohol solution includes adding an amount of alcohol to the active agent in a 1:1 ratio by volume.
[0029] In other examples, a method for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method includes: providing an animal broth; transforming the animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating an active agent by removing precipitates; removing the
transforming vehicle from the active agent; and forming the dietary supplement, wherein the dietary supplement includes the active agent. In some embodiments, the alcohol is ethanol.
[0030] An object of the subject matter of the present disclosure is to provide a dietary supplement that promotes an anti-inflammatory effect or barrier- promoting effect on the human gastrointestinal tract.
[0031] Another object of the subject matter of the present disclosure is to provide a dietary supplement that restores and/or improves an epithelial cell membrane integrity.
[0032] Another object of the subject matter of the present disclosure is to provide methods of preparation of such supplements.
[0033] Another object of the subject matter of the present disclosure is to provide methods of delivery of such supplements.
[0034] Another object of the subject matter of the present disclosure is to provide dietary supplements including an alcohol soluble fraction of meat broths and/or stocks, and their equivalents, wherein the supplement strengthens, protects, and repairs an epithelial cell layer in at least an in vitro assay for tight junction formation.
[0035] Another object of the subject matter of the present disclosure is to provide processes for heat extracting a source tissue followed by alcohol treatment and to provide processes for alcohol treatment of available broths and stocks.
[0036] An advantage of the subject matter of the present disclosure is that it provides supplements that promotes an anti-inflammatory effect or barrier- promoting effect on the human gastrointestinal tract.
[0037] Another advantage of the subject matter of the present disclosure is to provide a treatment method using natural food products without additional synthetic drugs that may have adverse side effects.
[0038] Another advantage of the subject matter of the present disclosure is that it provides a supplement that has nutritional value.
[0039] A further advantage of the subject matter of the present disclosure is that it provides a method of preparation that provides a supplement that does not require dilution and is compatible with a variety of common food and beverage ingredients to yield a desired flavor and texture profile.
[0040] Another advantage of the subject matter of the present disclosure is the fortification of normal wound healing processes using natural agents (i.e., not chemically synthesized) useful in maintaining gastrointestinal health and addressing gastrointestinal disorders.
[0041] Yet another advantage of the subject matter of the present disclosure is that it provides a cost-effective and efficient process for providing a supplement directly from biological sources.
[0042] Still another advantage of the subject matter of the present disclosure is that is teaches that commercially available food products, such as animal broths, can be transformed into dietary supplements that improve epithelial cell membrane integrity and barrier functions.
[0043] Additional objects, advantages and novel features of the examples will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following description and the accompanying drawings or may be learned by production or operation of the examples. The objects and advantages of the concepts may be realized and attained by means of the methodologies, instrumentalities and combinations particularly pointed out in the appended claims.
Brief Description of the Drawings
[0044] The drawing figures depict one or more implementations in accord with the present concepts, by way of example only, not by way of limitations. In the figures, like reference numerals refer to the same or similar elements.
[0045] Fig. 1 is a schematic of a tight junction.
[0046] Fig. 2 is a schematic overview of a TEE experimental design for measuring the integrity of Caco-2 epithelial membranes.
[0047] Fig. 3 is flow chart illustrating an example of a process for preparing a dietary supplement according to the present disclosure.
[0048] Fig. 4 is a flow chart of another example of a process for preparing a dietary supplement according to the present disclosure.
[0049] Fig. 5 is a graph of TEER data versus time showing the effects of a broth derived supplement on tight junctions in TEER assays.
[0050] Fig. 6 is a graph of TEER data versus time showing the effects of a gizzard derived supplement on tight junctions in TEER assays.
[0051] Fig. 7 is a bar graph denoting the ability of two chicken broth preparations to induce increased cell proliferation.
Detailed Description of the Invention
[0052] The supplements and methods described herein are based on the premise that unimpeded wound healing occurs when there is a full complement of both growth factors and wound healing proteins available at concentrations, and in a format, that favors immediate recruitment. Such composition can be achieved by: careful selection of proper starting material; a gentle disruptive hydrolysis, or other isolation or extraction technique to form extracted agents; selective transformation
of the extracted agents with ethanol to form transformed agents; and sequestration of the active transformed agents by phase separation techniques, or their equivalents; and the formation of a dietary supplement using the alcohol soluble components of the transformed agents.
[0053] Specifically, the present supplement compositions can be derived from natural sources. The natural sources may comprise an unpurified digest of animal tissue containing a complex mixture of proteins, peptides, growth factors, and nutrients associated with healthy tight junctions and homeostasis. The natural sources may be carefully selected for their healing characteristics. An example of a natural source is smooth animal muscle tissue, such as, but not limited to, stomachs, livers, and gizzards, from such as chicken, bovine, krill, sea urchin, and others.
[0054] In an example, the starting material is chicken gizzards, which are minced, and boiled in water for approximately 10-20 hours (e.g., 12 hours) to produce a chicken broth. Alternatively, the starting material can be commercially available meat broth (e.g., chicken broth, beef broth, among others). Other equivalent starting materials will be apparent to those skilled in the art based on the teachings provided herein.
[0055] When using an animal broth source material, whether commercially available or otherwise, the animal broth can be treated with a transforming vehicle, such as, but not limited to, ethanol. The amount of transforming vehicle used can be varied to achieve optimal levels of enrichment to form the active composition. In an example, the transforming vehicle can be used to convert an otherwise non-reactive broth into a formulation that positively affects tight junctions in an in vitro assay.
Transformation can be visually monitored and/or monitored by light microscopy, and/or monitored by measuring changes in optical density spectrophotometrically.
[0056] The alcohol soluble solution (including the active agents) can be decanted, wherein the formed precipitants are removed from the active agent solution. The active agent rich fractions can be combined based on desirable qualities. Following the removal of the transforming vehicle by simmering under low heat, the active agent solution can be selectively harvested by phase separation processes and processed into the supplement for delivery (e.g. concentrated solution, dried to a powder, converted to an elixir, among others).
[0057] In an example, the method of forming the composition can include combining the animal source (e.g., chicken gizzards) and distilled or deionized water in a 1:1 ratio in any suitable processing equipment intended to sufficiently reduce particle size to yield a smooth paste free of visible intact pieces. The paste can then be heated between 75°C and 95°C in a closed system capable of continuous mixing for a time period between 9 and 18 hours. The mixture can then be removed from the heat source and the liquid can be separated from any solids (e.g., precipitates) by centrifugation, filtration, and/or decanting, among other separation methods. The collected liquid can be combined with food-grade ethanol in proportions ranging from 1:1 to 1:3 parts liquid to ethanol. The ethanol and collected liquid mixture can be maintained at a temperature between 2°C to 6°C for a time period between 8 and 120 hours, during which time a precipitate forms in the mixture. The precipitate can be removed by any conventional means including, but not limited to, centrifugation, filtration, vacuum filtration, decanting, among others. The collected liquid free of precipitate can then be further purified to remove the ethanol from the
solution. The ethanol can be removed by employing any suitable process and/or processing equipment including, but not limited to, steam evaporation, rotary evaporation, heating the solution, among others. After the ethanol is removed, the solution can be further concentrated by suitable means in order to obtain a condensed active solution suitable for use. For example, the dilute solution can be dried via any common drying process that reduces the moisture level to a point that the dried invention is shelf-stable (e.g., 0.1% to 3.0% moisture). Suitable drying processes include, but are not limited to, freeze-drying, spray drying, agglomeration, drum drying, among others.
[0058] The supplement composition can include macronutrients, such as fats, carbohydrates, proteins, and fiber components. For example, the extracted agents from the source can include glutamine, phytochemicals, carotenoids, vitamin E, vitamin C, zinc, selenium, or combinations thereof.
[0059] The supplement composition can include various viscous fibers, such as, but not limited to guar gum, locust bean gum, xanthan gum, that may demonstrate an improved efficacy of the invention by forming a viscous 'bolus' that moves more slowly through the gut lumen than the untreated patient, thus increasing contact time with injured internal epithelial cells and allowing for increased efficacy in protecting, repairing, restoring, and maintaining healthy epithelial cells.
[0060] All materials, chemicals, and procedures used in the manufacture of the supplements taught herein may be "food safe" certified (e.g., designated as generally recognized as safe (GRAS) by the American Food and Drug Administration). The disclosed methods include selecting a source as a starting material (e.g. animal
muscle tissue) that is minced into small pieces, converted into a puree (or smooth paste), or subject to any other particle reduction mechanism that increases the surface area of the starting material to then promote the release of the agent by a gentle heat or enzyme digestion. The soluble extracted agent can be collected by selective phase precipitation, filtration, or electrochemical or chromatographic methodologies.
[0061] The delivery method of the supplement comprising the active agents depends on the specific application and biological efficacy desired. For example, following removal of the transforming vehicle, the active agents can be incorporated into a supplement that can be administered directly as a food, candy, drink, mouthwash, among others. For example, the composition can be included in a dilute liquid form that may be utilized as a base for liquids such as hot or cold beverages (carbonated and/or still), soups, broths, syrups, juice, vegetable extracts, caffeinated beverages, among others. The composition can include flavor, color, among other additives. In addition, the supplement can be included in or as food additives, gummies, chewing gum, candy, lozenges, lollipops, antacid formulations, or hydrogels. For example, the composition can be included in a formula using a liquid ingredient for the purpose of hydrating a powdered matrix, such as flours used in the manufacture of pastas, baked goods, snack foods, among many others. Alternatively, the composition can be provided in a powder form that can be incorporated in recipes using dry ingredients that may be post-processed in any manner of methods specific to the end product. For example, the dry form of the composition can be used in shelf-stable prepared meals, such as macaroni and cheese, among others. The supplement can include a timed-released coatings, hydrogels, or carriers that
can modulate bioavailability. The formulation can also be combined with other identified agents that can promote Gl tract health, like probiotics.
[0062] The composition can be formed into a supplement prepared using methods known to the skilled person. For example, alcohol soluble components (i.e., the composition solution free of participates) can be encapsulated at appropriate dosage concentrations with various substances conventionally used as gelling agents or thickening agents in the field of food products. Examples of gelling agents include agar, gellan gum, carrageenan, pectin, pre- gelatinized starch, modified starch and gelatin. Examples of thickening agents include furceliaran, locust bean gum, guar gum, gum Arabic and xanthan gum. These gelling agents and thickening agents can be used singly or in combination. The combination of a gelling agent and a thickening agent is especially preferable. Gelling agents and/or thickening agents exhibit an appropriate gelling ability and gel stabilizing ability and control the gel strength of the resulting gel.
[0063] The supplement can be a nutritional supplement, which can be administered to the patient in a single dose, via multiple doses over a course of treatment, or on a routine ongoing basis. For example, the supplement can be administered in a single dose once, twice, or three times per day. In another example, the supplement may be administered up to five times per day. In still other examples, the supplement may be administered between three to seven times per day. For example, the supplement can be part of a vitamin regimen or probiotic supplement.
[0064] The supplement can include a flavor to enhance its palatability, especially in a pediatric population. Artificial sweeteners may be added to
complement: the flavor and mask the salty taste. Useful artificial sweeteners include saccharin, NutraSweet, sucraiose, acesu!fane-K (ace-K), etc,
[0065] Preservatives may be added to help extend shelf life of the supplement. Persons knowledgeable in the art will be able to select the appropriate preservative, in the proper amount, to accomplish this result. Typical preservatives include, but are not limited to, potassium sorbate and sodium benzoate.
[0066] In addition, the supplement can include suitable carbohydrates, lipids and proteins as are known to those skilled in the art of making nutritional formulas. Suitable carbohydrates include, but are not limited to, hydroiyzed, intact, naturally and/or chemically modified starches sourced from corn, tapioca, rice or potato in waxy or non-waxy forms; and sugars such as glucose, fructose, lactose, sucrose, maltose, high fructose corn syrup, corn syrup solids, fructo-oligosaccharides, and mixtures thereof. Ma!todextrins are polysaccharides obtained from the acid or enzyme hydrolysis of starches (such as those from corn or rice).
[0067] Fig. 1 is a schematic of an example of a tight junction. Differentiated human Caco-2 cells are a useful model of the intestinal barrier with functional tight junction complexes. Caco-2 cells can form an artificial epithelial cell membrane that can be challenged with nutrients and toxins. Integrity of this membrane can be monitored with a TEER assay format and agents can be screened for their ability to improve or destroy intestinal barrier function. A metric of enhanced protection of barrier function is the achievement of a level of TEER values 100% or higher than the control.
[0068] For example, Fig. 2 shows an overview of a TEER experimental design for measuring the integrity of Caco-2 epithelial membranes. In the example shown in
Fig. 2, trans-epithelial electrical resistance (TEER) readings are performed at discreet, designated time points (e.g., 0, 28, and 48 hours, etc.) using an epithelial voltohmmeter, such as the one sold under the trademark name EVOM2 by World Precision Instruments, or continuously (e.g., for 24 continuous hours, for 48 continuous hours, etc.) or at hourly intervals using a cell monitoring system, such as the one sold under the trademark name CellZscope by nanoAnalytics GmbH. Higher potentials correspond to greater membrane integrity. The lower the potential, the more disruption of the membrane.
[0069] In the example shown, the experimental design tests food grade samples for effects on intestinal barrier function in cultured intestinal cells. Caco-2 cells are cultured on plates (such as those sold under the trademark name Transwell by Corning Incorporated) and cultured for 21 days to form a model intestinal barrier. Subsequently, cells are treated with test compounds, with or without an
inflammatory stimulus (inflammatory cocktail, IC), composed of proinflammatory cytokines and lipopolysaccharaide (LPS). The inflammatory cocktail treatment induces intestinal barrier dysfunction. Test compounds that prevent IC-induced barrier dysfunction may have anti-inflammatory cytokines and lipopolysaccharide (LPS). Test compounds that prevent IC-induced barrier dysfunction may have antiinflammatory and/or barrier-promoting activities. Test compounds that increase barrier function in healthy cells likely have barrier-promoting activities. In the example shown, genistein, a soy isoflavone, is used as a positive control. Barrier function is determined by trans-epithelial electrical resistance (TEER) and reported and described in Equations 1 and 2.
TEE (Δ% Initial) = 100 * (TEER 24 or 28 hours - TEE R o hour)/TEER o hour (1) TEER (Δ% IC Normalized) = 100 * TEER (Δ% lnitial)sampie/ TEER (Δ% lnitial)ic (2)
[0070] On day 20 of growth, the EVOM2 voltohmmeter is prepared by plugging it in and placing the "chopstick" electrode in .1 M KOH. On day 21, the cultured Caco-2 cell samples are processed as follows, or equivalent.
[0071] For example, 24-well plates containing membrane inserts with Caco-2 cells are removed from a C02 incubator (37°C, 5% C02, ~91% Relative Humidity) and moved into a biosafety hood. The modified growth media is removed from both the basal and apical layers of the cell inserts. The cells are washed with sterile phosphate buffered solution and a Hanks Balanced Salt Solution (HBSS) is added to the apical (.2 ml) and basal layers (1 ml). The 24-well plates are returned to the C02 incubator and allowed to incubate for 30 minutes. A hotplate in the biosafety hood is set to 37°C and the EVOM2, along with the chopstick electrodes, are moved to the biosafety hood. The chopstick electrodes are submerged in 70% ethanol solution for 15 minutes and then held in the HBSS. At 30 minutes, each plate is removed from the incubator one by one and placed on the hot plate. The covers are removed and, using the "chopstick" electrodes, each insert is measured in triplicate. The average of the three measurements establishes a baseline for each insert. When all the inserts have been measured, the plate is returned to the hood, and the next plate is measured. Once all the plates have been measured, they are brought into the biosafety hood again for the introduction of experimental media and inflammatory cocktail at time T=0.
[0072] At time T=0, the HBSS is removed from both the apical and basal compartments and replaced with inflammatory cocktail (or experimental growth media, in the case of positive controls) and experimental media in the apical layer according to the experimental design. The plates are returned to the C02 incubator for 24-hours. At 24-hours, the plates are removed from the incubator and the measurements are repeated. In instances in which 48 hour measurements are taken, another set of measurements are taken at T=48 hours. Once the final measurements are taken, the cells are terminated using a 10% bleach solution and disposed of according to biosafety hazard protocols.
[0073] In this example, dry samples are prepared by weighing out 10 mg of material into 15 mL conical centrifuge tubes, re-suspending dry material in modified DM EM growth media, vortexing at 2000 PM for 30 seconds, and sonicating at 37°C for 20 minutes. The solutions are then filtered using a .2-micron syringe tip filter. This stock solution is then used to create samples of the desired concentration by diluting the sterile stock solutions further with the modified growth media.
[0074] In this example, liquid samples are prepared by thawing liquid samples in a hot water bath at 37°C for about 5 minutes or until fully thawed, adding the volume of supplied liquid to modified DMEM growth media, and filtering the solutions using a .2-micron syringe tip filter. This stock solution is then used to create samples of the desired concentration by diluting the sterile stock solutions further with the modified growth media.
[0075] In the example shown, the inflammatory cocktail is prepared by the following process: concentrated stock solutions of the necessary cytokines are stored in the -80°C freezer and properly aliquoted to minimize degradation from
thaw-freeze cycles. The cytokine aliquots are removed from the freezer and brought into the hood for processing. The cytokines are added to the modified growth media to arrive at the final concentration of 50 ng/ml (TNF-a), 25 ng/ml (IL-Ιβ), 50 ng/ml (IFN-γ), 1 μg/ml (Lipopolysaccharide).
[0076] Figs. 3 and 4 illustrate examples of processes for preparing dietary supplements according to the teachings presented herein. These examples are illustrative of the subject matter of this disclosure.
[0077] Fig. 3 illustrates an example of a process for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method comprises the steps of: providing an animal broth; transforming the animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol; isolating an active agent by removing precipitates; removing the transforming vehicle from the active agent; and forming the dietary supplement, wherein the dietary supplement includes the active agent. In some examples of the method shown in Fig. 3, the alcohol is ethanol.
[0078] In an example of the process illustrated in Fig. 3, the process for preparing a dietary supplement for improving gastrointestinal functionality can include selecting an animal broth. The selected animal broth may be a commercially available chicken broth such as, for example, the animal broth sold under the trademark name Swanson Unsalted Chicken Broth by CSC Brand LP. In other examples, the animal broth may be a different chicken broth or may be an animal broth other than a chicken broth, for example, a beef broth. Suitable animal broths will be recognized by those skilled in the art based on the practice of the inventions described herein.
[0079] In an example of the process illustrated in Fig. 3, the step of transforming the animal broth into an active agent by adding a transforming vehicle to the animal broth may include combining the animal broth with food-grade ethanol in proportions ranging from 1:1 to 1:3 parts liquid to ethanol. The ethanol and collected liquid mixture can be maintained at a temperature between 2°C to 6°C for a time period between 8 and 120 hours, during which time a precipitate forms in the mixture.
[0080] In an example of the process illustrated in Fig. 3, the step of isolating an active agent by removing precipitates can be accomplished by any conventional means including, but not limited to, centrifugation, filtration, vacuum filtration, decanting, among others.
[0081] In an example of the process illustrated in Fig. 3, the step of removing the transforming vehicle from the active agent can include further purification of the active agent by removing the ethanol from the solution. The ethanol can be removed by employing any suitable process and/or processing equipment including, but not limited to, steam evaporation, rotary evaporation, heating the solution, among others.
[0082] After the ethanol is removed the step of removing the transforming vehicle from the active agent can additionally include further concentration of the active agent in order to obtain a condensed active agent suitable for use. For example, the dilute solution can be dried via any common drying process that reduces the moisture level to a point that the dried invention is shelf-stable (e.g., 0.1% to 3.0% moisture). Suitable drying processes include, but are not limited to, freeze-drying, spray drying, agglomeration, drum drying, among others.
[0083] In an example of the process illustrated in Fig. 3, the step of forming the dietary supplement, wherein the dietary supplement includes the active agent, may include, as described in detail above, incorporating the active agent into a supplement that can be administered directly as an edible supplement in the form of a food, candy, drink, mouthwash, etc. Additional details as to the processes and compositions are included above in this detailed description.
[0084] Fig. 4 illustrates an example of a process for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method comprises the steps of: selecting a biological source; applying heat to the biological source to release a biological agent from the biological source; isolating the biological agent from the biological source to form an extracted agent; transforming the extracted agent into an active agent by treating the extracted agent with an alcohol solution; and forming the dietary supplement, wherein the dietary supplement includes the active agent.
[0085] In an example of the process illustrated in Fig. 4, the process for selecting a biological source may include selecting chicken gizzards as a biological source. In alternative examples, another animal tissue may be used as the biological source.
[0086] In an example of the process illustrated in Fig. 4, the process for applying heat to the biological source to release a biological agent from the biological source may include mincing the chicken gizzards (or other animal tissue), and then boiling them in water for approximately 10-20 hours (e.g., 12 hours) to produce a chicken broth. For example, chicken gizzards can be combined with distilled or deionized water in a 1:1 ratio in any suitable processing equipment
intended to sufficiently reduce particle size to yield a smooth paste (or puree) free of visible intact pieces. The paste can then be heated between 75°C and 95°C in a closed system capable of continuous mixing for a time period between 9 and 18 hours.
[0087] In an example of the process illustrated in Fig. 4, isolating the biological agent from the biological source to form an extracted agent may include removing the heated biological source from the heat source and separating liquid from any solids (e.g., precipitates) by centrifugation, filtration, and/or decanting, among other separation methods. The separated liquid is the extracted agent.
[0088] In an example of the process illustrated in Fig. 4, transforming the extracted agent into an active agent by treating the extracted agent with an alcohol solution includes combining the extracted agent (i.e., the separated liquid) with food-grade ethanol in proportions ranging from 1: 1 to 1:3 parts liquid to ethanol. The ethanol and liquid mixture can be maintained at a temperature between 2°C to 6°C for a time period between 8 and 120 hours, during which time a precipitate forms in the mixture. The precipitate can be removed by any conventional means including, but not limited to, centrifugation, filtration, vacuum filtration, decanting, among others. The collected liquid free of precipitate can then be further purified to remove the ethanol from the solution. The ethanol can be removed by employing any suitable process and/or processing equipment including, but not limited to, steam evaporation, rotary evaporation, heating the solution, among others. After the ethanol is removed, the solution can be further concentrated by suitable means in order to obtain a condensed active solution suitable for use. For example, the dilute solution can be dried via any common drying process that reduces the
moisture level to a point that the dried invention is shelf-stable (e.g., 0.1% to 3.0% moisture). Suitable drying processes include, but are not limited to, freeze-drying, spray drying, agglomeration, drum drying, among others.
[0089] In an example of the process illustrated in Fig. 4, forming the dietary supplement, wherein the dietary supplement includes the active agent, includes, as described in detail above, incorporating the active agent into a supplement that can be administered directly as an edible supplement in the form of a food, candy, drink, mouthwash, etc. Additional details as to the processes and compositions are included above in this detailed description.
[0090] Turning now to experimental results obtained when testing the subject matter presented herein, Fig. 5 is a graph of TEER data versus time showing the effects of a broth derived supplement on tight junctions in TEER assays. Similarly, Fig. 6 is a graph of TEER data versus time showing the effects of a gizzard derived supplement on tight junctions in TEER assays.
[0091] The results shown in Figs. 5 and 6 are representative of results obtained by following the TEER experimental design for measuring the integrity of Caco-2 epithelial membranes described above with respect to Fig. 2. As shown on the x-axis, TEER readings were taken every hour between T=0 and T=48. The y-axis represents the barrier function of the Caco-2 epithelial membranes as determined by trans-epithelial electrical resistance (TEER) plotted as TEER (Δ% Initial) = 100 * (TEER 24 or 28 hours - TEER o hour)/TEER o hour- TEER readings below 100 are representative of diminished epithelial membrane integrity resulting in diminished barrier function of the epithelial membrane. TEER readings above 100 are representative of restored
or enhanced epithelial membrane integrity and enhanced barrier function in the epithelial membranes.
[0092] In the example shown in Fig. 5, the experiment was run for two inflammatory cocktails, a commercial chicken broth combined with an inflammatory cocktail, a 5 mg/mL liquid preparation of the alcohol-soluble components of the commercial chicken broth combined with an inflammatory cocktail, and a 10 mg/mL liquid preparation of the alcohol-soluble components of the commercial chicken broth combined with an inflammatory cocktail.
[0093] As shown in Fig. 5, the inflammatory cocktails resulted in diminished barrier function of the epithelial membrane throughout the 48-hour testing period. Neither the untreated commercially available chicken broth, nor the 5 mg/mL liquid preparation of the alcohol-soluble components of the commercial chicken broth were able to fully counteract the effects of the inflammatory cocktail, each showing diminished barrier function of the epithelial membrane throughout the 48-hour testing period. However, the 10 mg/mL liquid preparation of the alcohol-soluble components of the commercial chicken broth showed increased barrier function throughout the majority of the 48-hour testing period. Accordingly, the results shown in Fig. 5 support the conclusion that a liquid-based dietary supplement including a concentration of approximately, or at least, 10 mg/mL of alcohol-soluble preparation derived from commercially available chicken broth may provide enhanced barrier function of tight junctions.
[0094] In the example shown in Fig. 6, the experiment was run for an inflammatory cocktail, a 25 mg/mL powder preparation of an animal broth made from chicken gizzards combined with an inflammatory cocktail, a 25 mg/mL powder
preparation of the alcohol-soluble components of an animal broth made from chicken gizzards combined with an inflammatory cocktail, and a 25 mg/mL liquid preparation of the alcohol-soluble components of an animal broth made from chicken gizzards combined with an inflammatory cocktail.
[0095] As shown in Fig. 6, just as in Fig. 5, the inflammatory cocktail resulted in diminished barrier function of the epithelial membrane throughout the 48-hour testing period. The 25 mg/mL powder preparation of an animal broth made from chicken gizzards was unable to counteract the inflammatory cocktail and, therefore, showed diminished barrier function of the epithelial membrane throughout substantially all of the 48-hour testing period. However, both the 25 mg/mL powder preparation of the alcohol-soluble components of an animal broth made from chicken gizzards and the 25 mg/mL liquid preparation of the alcohol-soluble components of an animal broth made from chicken gizzards showed increased barrier function throughout a statistically relevant portion of the 48-hour testing period. Accordingly, the results shown in Fig. 6 support the conclusion that both powder-based and liquid-based dietary supplements including a concentration of approximately, or at least, 25 mg/ML of the alcohol-soluble components of an animal broth made from chicken gizzards may provide enhanced barrier function of tight junctions.
[0096] Figs. 5 and 6 are representative examples of testing that has been performed on the subject matter presented herein. Numerous assays were completed with redundant sources and preparations demonstrating repeatable results.
[0097] Fig. 7 illustrates a pair of bar graphs showing the cell proliferation of a
Caco-2 epithelial membrane when subjected to various compositions. In the example shown in Fig. 7, mitogenesis was assayed by performing cell counts four days after exposing a confluent culture of indicator cells to the agent of interest, adding trypsin to prepare a suspension of single cells, and confirming cell separation while counting them in a hemocytometer. Mitogenic activity was assessed in each of the following preparations: chicken gizzard derived supplement using no alcohol extraction step (Sample 1), and chicken broth derived supplement that utilized an alcohol treatment step (Sample 2).
[0098] Although both compositions caused an increase in cell proliferation, in an in vitro assay, as shown, the compositions of ethanol-treated commercial chicken broth (Sample 2) demonstrated superior cell proliferation relative to the control . Moreover, the compositions of ethanol-treated commercial chicken broth (Sample 2) further demonstrated a dose dependency, with the higher concentrations showing greater cell proliferation. Greater cell proliferation represents a restoration and/or enhancement of the barrier function of the epithelial membrane and is suggestive of wound repair and healthy tight junctions.
[0099] Accordingly, the subject matter provided herein supports a conclusion that, in the appropriate concentration, the alcohol-soluble components of both "off- the-shelf" commercially available animal broths, as well as animal broths developed from animal tissue such as chicken gizzards, demonstrate the ability to restore and/or improve epithelial membrane integrity and barrier function.
[00100] In experiments related to those represented by Figs. 5 and 6, TEE data demonstrated the effects of residual ethanol in the broth digests. When
residual ethanol was present (i.e., not completely boiled off from the active agent solution), TEER measurements were lower than the inflammatory cocktail tracings. Accordingly, this data demonstrates that there are advantages to completely removing any residual ethanol in the broth digests.
[00101] It should be noted that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages.
Claims
1. A dietary supplement comprising: an edible supplement comprising at least 10 mg/mL of alcohol soluble components of an animal broth.
2. The dietary supplement of claim 1, wherein the dietary supplement is in the form of at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel.
3. The dietary supplement of claim 1, wherein the dietary supplement is derived from commercially available chicken broth.
4. The dietary supplement of claim 1, wherein the dietary supplement is derived from an animal broth including one or more chicken gizzards.
5. The dietary supplement of claim 1, wherein the dietary supplement is prepared by:
transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol;
isolating the active agent by removing precipitates;
removing the transforming vehicle from the active agent; and
forming the dietary supplement, wherein the dietary supplement includes the active agent.
6. A dietary supplement comprising:
a concentrated animal broth derived from an animal source, wherein the concentrated broth is active by a transforming vehicle, wherein the transforming vehicle is an alcohol.
7. The dietary supplement of claim 6, wherein the transforming vehicle is removed from the dietary supplement.
8. The dietary supplement of claim 6, wherein the dietary supplement includes at least 10 mg/mL of alcohol soluble components of the animal broth.
9. The dietary supplement of claim 6, wherein the dietary supplement includes at least 25 mg/mL of alcohol soluble components of the animal broth.
10. The dietary supplement of claim 6, wherein the dietary supplement is in the form of at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel.
11. A method for preparing a dietary supplement for improving gastrointestinal functionality, wherein the method comprises the steps of:
transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth, wherein the transforming vehicle is an alcohol;
isolating the active agent by removing precipitates;
removing the transforming vehicle from the active agent; and
forming the dietary supplement, wherein the dietary supplement includes the active agent.
12. The method of claim 11, wherein the step of transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth includes combining the extracted agent with an ethanol solution, decanting the supernatant, and concentrating the supernatant solution to form the active agent.
13. The method of claim 11, further comprising the step of, after transforming the extracted agent into the active agent, heating the active agent to remove a majority of the alcohol.
14. The method of claim 11, further comprising incorporating the dietary supplement into at least one of a food product, hydrogel, solution, tablet, lozenge, vitamin, powder, candy, and gel.
15. The method of claim 11, wherein the step of transforming an animal broth into an active agent by adding a transforming vehicle to the animal broth includes adding an amount of alcohol to the animal broth in a 1:1 ratio by volume.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880003901.2A CN110139567A (en) | 2017-01-19 | 2018-01-19 | For gastrointestinal inflammatory dietary supplements and preparation method thereof |
EP18741945.2A EP3570686A4 (en) | 2017-01-19 | 2018-01-19 | Dietary supplement for gastrointestinal inflammation and method for making the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762448151P | 2017-01-19 | 2017-01-19 | |
US62/448,151 | 2017-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018136832A1 true WO2018136832A1 (en) | 2018-07-26 |
Family
ID=62838189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/014582 WO2018136832A1 (en) | 2017-01-19 | 2018-01-19 | Dietary supplement for gastrointestinal inflammation and method for making the same |
Country Status (4)
Country | Link |
---|---|
US (2) | US20180199608A1 (en) |
EP (1) | EP3570686A4 (en) |
CN (1) | CN110139567A (en) |
WO (1) | WO2018136832A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2352549A1 (en) * | 1976-05-25 | 1977-12-23 | Dulong Daniel | Treatment of hepatic insufficiency - by oral or parenteral admin. of gizzards or an extract |
CA2290885A1 (en) * | 1999-12-02 | 2001-06-02 | Universite De Sherbrooke | Method for processing harbour seal tissues |
JP4712256B2 (en) * | 2001-09-28 | 2011-06-29 | 東海物産株式会社 | High-grade chicken extract-containing functional food and method for producing the same |
JPWO2008007667A1 (en) * | 2006-07-10 | 2009-12-10 | キリン協和フーズ株式会社 | Chicken extract and method for producing chicken extract |
WO2012158048A1 (en) * | 2011-05-16 | 2012-11-22 | Vital Food Processors Limited | A dietary supplement |
CN103524597A (en) * | 2012-07-03 | 2014-01-22 | 浙江海洋学院 | Antioxidant peptide prepared from shark prolamin and preparation method and application thereof |
CN103351422B (en) * | 2013-07-16 | 2015-04-22 | 浙江工商大学 | Method for extracting natural bioactive protein from unpolished rice or/and rice bran |
CN104095264A (en) * | 2014-05-10 | 2014-10-15 | 安徽林苑农副食品有限公司 | Walnut chicken soup and preparation method thereof |
CN106136173A (en) * | 2016-06-30 | 2016-11-23 | 柳州沪桂食品有限公司 | A kind of health nutrient chicken soup |
-
2018
- 2018-01-19 WO PCT/US2018/014582 patent/WO2018136832A1/en unknown
- 2018-01-19 EP EP18741945.2A patent/EP3570686A4/en not_active Withdrawn
- 2018-01-19 CN CN201880003901.2A patent/CN110139567A/en active Pending
- 2018-01-19 US US15/876,098 patent/US20180199608A1/en not_active Abandoned
-
2022
- 2022-01-28 US US17/587,704 patent/US20220151275A1/en active Pending
Non-Patent Citations (6)
Title |
---|
BRANCH: "Homemade Chicken Stock", SUSAN BRANCH BLOG, 18 November 2016 (2016-11-18), XP055505188, Retrieved from the Internet <URL:https://web.archive.org/web/20161118132815/http://www.susanbranch.com/homemade-old-fashioned-chicken-stock-recipe-from-the-heart-of-the-home> [retrieved on 20180222] * |
JOYBILEE FARM: "6 Tips for the Best Bone Broth: Never Open a Can of Soup Again", JOYBILEE FARM BLOG, 2 August 2016 (2016-08-02), XP055505192, Retrieved from the Internet <URL:https://joybileefarm.com/6-tips-best-bone-broth> [retrieved on 20180222] * |
NDTV FOOD: "What Happens to Wine When it is Cooked?", OPINIONS, 17 July 2014 (2014-07-17), XP055505200, Retrieved from the Internet <URL:https://food.ndtv.com/opinions/what-happens-to-wine-when-it-is-cooked-695664> [retrieved on 20180222] * |
SANDLER: "The Magic of Broths: Beef Stock", EDIBLE COMMUNITIES, 9 June 2016 (2016-06-09), XP055505197, Retrieved from the Internet <URL:http://www.ediblecommunities.com/recipes/magic-broths-beef-stock> [retrieved on 20180227] * |
See also references of EP3570686A4 * |
SLAJEROVA: "Keto Bone Broth", THE KETODIET BLOG, 13 January 2015 (2015-01-13), XP055505179, Retrieved from the Internet <URL:https://ketodietapp.com/Blog/post/2015/01/13/Keto-Bone-Broth?print=recipeNoImages> [retrieved on 20180221] * |
Also Published As
Publication number | Publication date |
---|---|
EP3570686A1 (en) | 2019-11-27 |
US20180199608A1 (en) | 2018-07-19 |
US20220151275A1 (en) | 2022-05-19 |
EP3570686A4 (en) | 2021-01-06 |
CN110139567A (en) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102802636B (en) | Crocin hydrolysate | |
RU2499604C2 (en) | Planch and inflammation | |
Hunter et al. | Kiwifruit and health | |
CZ39699A3 (en) | Mixtures of vegetable carbohydrates functioning as foodstuff complements | |
TWI516280B (en) | Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging | |
JP2004250445A (en) | Glycation inhibitor and its use | |
KR20160101724A (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
US20080124416A1 (en) | Therapeutic composition from goji (lycium barbarum l.), methods of making and using | |
KR20100105598A (en) | Sense-improving agent | |
Salla et al. | A comparative study on the role of Omani honey with various food supplements on diabetes and wound healing | |
KR101896024B1 (en) | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same | |
RU2491083C2 (en) | Using phytoecdysone and preparing compositions for treating metabolic syndrome | |
AU2006347122B2 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus Acacia | |
JP2002255846A (en) | Oral composition | |
KR101782134B1 (en) | Health care food of composition comprising the extract material in garcinia cambogia | |
US20220151275A1 (en) | Dietary Supplement for Gastrointestinal Inflammation and Method for Making the Same | |
US9737583B2 (en) | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient | |
KR20190113725A (en) | A composition for improving Memory and cognitive function comprising using Dendropanax morbiferus Lev. | |
WO2007007994A1 (en) | Food composition for improving liver function comprising a lonicera caerulea l. var. edulis extract | |
CN111387394A (en) | Sea-buckthorn solid beverage for enhancing immunity and inhibiting tumors and preparation method thereof | |
KR101714568B1 (en) | A composition comprising an extract of combined crude drugs for treating and preventing PADAM syndrome | |
KR20130134733A (en) | Composition for improving liver function containing fermented liquor of codonopsis lanceolata extract as effective component | |
KR20200120549A (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
WO2016206363A1 (en) | Use of jilin ginseng oligopeptide in preparation of anti-oxidant food product or health care food product | |
JP7090864B2 (en) | Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18741945 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018741945 Country of ref document: EP Effective date: 20190819 |